Michael Yee
Stock Analyst at UBS
(4.10)
# 490
Out of 5,147 analysts
111
Total ratings
52.56%
Success rate
13.96%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Neutral | $100 → $115 | $113.79 | +1.06% | 2 | Feb 24, 2026 | |
| GLTO Galecto | Initiates: Buy | $45 | $29.58 | +52.13% | 1 | Feb 17, 2026 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $230 | $232.08 | -0.90% | 2 | Feb 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $535 → $545 | $496.83 | +9.70% | 6 | Jan 26, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $155 | $148.95 | +4.06% | 5 | Jan 26, 2026 | |
| AMGN Amgen | Maintains: Buy | $380 → $390 | $388.16 | +0.47% | 7 | Jan 26, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Neutral | $20 → $14 | $13.97 | +0.21% | 3 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Assumes: Buy | $50 | $32.20 | +55.28% | 1 | Jan 7, 2026 | |
| DNLI Denali Therapeutics | Assumes: Buy | $25 | $21.18 | +18.04% | 3 | Jan 7, 2026 | |
| IMCR Immunocore Holdings | Assumes: Buy | $24 → $55 | $32.30 | +70.28% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $3 → $12 | $6.49 | +84.90% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 → $70 | $55.05 | +27.16% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $29.38 | +70.18% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $44.27 | +35.53% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $12.06 | +49.25% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.10 | +70.73% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $34.41 | +45.31% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $24.20 | +85.95% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.91 | +69.20% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $32.55 | +84.33% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $26.80 | +86.57% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $28.46 | -1.62% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.78 | +187.77% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.22 | +82.10% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.03 | +184.50% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $62.37 | +4.22% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $130 → $185 | $191.82 | -3.56% | 6 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $25 | $27.65 | -9.58% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $1,051.99 | +18.82% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $2.11 | +42.18% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $53.57 | +2.67% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $542.40 | -29.02% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $4.99 | -39.88% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $13.80 | +44.93% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.35 | +795.52% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $8.67 | +246.02% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $29.84 | +302.14% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $74.13 | -59.53% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $21.70 | +254.84% | 2 | Nov 8, 2018 |
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $100 → $115
Current: $113.79
Upside: +1.06%
Galecto
Feb 17, 2026
Initiates: Buy
Price Target: $45
Current: $29.58
Upside: +52.13%
AbbVie
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $232.08
Upside: -0.90%
Vertex Pharmaceuticals
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $496.83
Upside: +9.70%
Gilead Sciences
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $148.95
Upside: +4.06%
Amgen
Jan 26, 2026
Maintains: Buy
Price Target: $380 → $390
Current: $388.16
Upside: +0.47%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Neutral
Price Target: $20 → $14
Current: $13.97
Upside: +0.21%
IDEAYA Biosciences
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $32.20
Upside: +55.28%
Denali Therapeutics
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $21.18
Upside: +18.04%
Immunocore Holdings
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $32.30
Upside: +70.28%
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $6.49
Upside: +84.90%
Jan 7, 2026
Assumes: Buy
Price Target: $20 → $70
Current: $55.05
Upside: +27.16%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $29.38
Upside: +70.18%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $44.27
Upside: +35.53%
Jan 7, 2026
Initiates: Neutral
Price Target: $18
Current: $12.06
Upside: +49.25%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $4.10
Upside: +70.73%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $34.41
Upside: +45.31%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $24.20
Upside: +85.95%
Jan 7, 2026
Initiates: Neutral
Price Target: $10
Current: $5.91
Upside: +69.20%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $32.55
Upside: +84.33%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $26.80
Upside: +86.57%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $28.46
Upside: -1.62%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.78
Upside: +187.77%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $19.22
Upside: +82.10%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $7.03
Upside: +184.50%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $62.37
Upside: +4.22%
Jan 7, 2026
Assumes: Neutral
Price Target: $130 → $185
Current: $191.82
Upside: -3.56%
Jan 7, 2026
Assumes: Neutral
Price Target: $25
Current: $27.65
Upside: -9.58%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $1,051.99
Upside: +18.82%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $2.11
Upside: +42.18%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $53.57
Upside: +2.67%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $542.40
Upside: -29.02%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $4.99
Upside: -39.88%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $13.80
Upside: +44.93%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.35
Upside: +795.52%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $8.67
Upside: +246.02%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $29.84
Upside: +302.14%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $74.13
Upside: -59.53%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $21.70
Upside: +254.84%